Partner Mark Izraelewicz and several members of Marshall Gerstein's litigation team received praise in Law.com's Litigator of the Week Runners-Up and Shout Outs for their work on a high-profile intellectual property infringement lawsuit involving our client CureVac.
"Shout-out to Mark Izraelewicz and his team at Marshall, Gerstein & Borun, who have represented CureVac in patent litigation against Pfizer and BioNTech over claims that the Pfizer/BioNtech COVID-19 vaccine, Comirnaty, infringes CureVac's messenger RNA patents. After U.S. District Judge Jamar Walker in Norfolk, Virginia, issued a favorable Markman ruling last year and denied the defendants' motion for summary judgment earlier this year, CureVac announced a settlement last week that will pay it and its partner GSK a total of $740 million and single-digit royalties on sales of COVID-19 vaccines in the U.S. going forward. The Marshall Gerstein team included Kevin Flowers, John Labbé, Michael Weiner, Sandip Patel, Michael Allikian, Thomas Burns, Izabella Higson, Daniel Gonzalez Jr. and Christopher Hall."
Read more about the case here:
CureVac's Patent Settlement: A Strategic Win for mRNA Innovation and Future Revenue Streams
GSK collects $320M as BioNTech, Pfizer settle mRNA patent spat with CureVac | Fierce Pharma